XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q3)Dec 31, 2024 | (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 6.76%1.34B | 5.58%1.12B | 11.67%1.09B | -5.30%4.3B | 5.35%1.01B | -1.14%1.26B | -8.00%1.06B | -15.98%974.5M | -17.19%4.54B | -21.94%960.08M |
Operating revenue | 6.76%1.34B | 5.58%1.12B | 11.67%1.09B | -5.30%4.3B | 5.35%1.01B | -1.14%1.26B | -8.00%1.06B | -15.98%974.5M | -17.19%4.54B | -21.94%960.08M |
Cost of revenue | 5.10%765.85M | 1.87%629.94M | 3.86%621.96M | -10.60%2.52B | -6.77%574.51M | -8.07%728.69M | -12.92%618.39M | -14.48%598.86M | -12.39%2.82B | -16.29%616.21M |
Gross profit | 9.05%574.44M | 10.82%486.09M | 24.12%466.26M | 3.40%1.78B | 27.08%436.98M | 10.37%526.78M | -0.04%438.62M | -18.27%375.64M | -24.02%1.72B | -30.38%343.86M |
Operating expense | 11.82%339.78M | 14.52%324.97M | 6.28%311.21M | -2.93%1.18B | 7.64%299.43M | 3.19%303.87M | -5.48%283.77M | -14.76%292.81M | -17.69%1.22B | -22.82%278.19M |
Selling and administrative expenses | 13.23%259.17M | 16.11%246.04M | 6.21%233.2M | -4.45%882.62M | 8.10%221.36M | 1.27%228.89M | -7.20%211.89M | -17.03%219.57M | -20.98%923.74M | -26.63%204.77M |
-Selling and marketing expense | 14.73%217.05M | 14.46%201.86M | 9.89%196.91M | -9.75%730.31M | 2.50%185.59M | -3.80%189.18M | -12.73%176.36M | -21.88%179.19M | -21.12%809.18M | -26.70%181.06M |
-General and administrative expense | 6.06%42.12M | 24.30%44.17M | -10.12%36.3M | 32.95%152.31M | 50.83%35.76M | 35.24%39.71M | 35.44%35.54M | 14.57%40.38M | -19.91%114.56M | -26.04%23.71M |
Research and development costs | 7.25%77.97M | 11.15%76.21M | 6.73%75.31M | 2.30%287.24M | 6.78%75.42M | 10.76%72.7M | -0.65%68.56M | -6.57%70.56M | -3.79%280.8M | -9.92%70.63M |
Depreciation amortization depletion | 15.86%2.64M | -17.87%2.73M | 0.67%2.7M | -7.68%10.93M | -4.87%2.66M | -19.00%2.28M | 15.49%3.32M | -20.30%2.69M | -30.12%11.84M | -5.74%2.79M |
-Depreciation and amortization | 15.86%2.64M | -17.87%2.73M | 0.67%2.7M | -7.68%10.93M | -4.87%2.66M | -19.00%2.28M | 15.49%3.32M | -20.30%2.69M | -30.12%11.84M | -5.74%2.79M |
Operating profit | 5.27%234.67M | 4.05%161.13M | 87.19%155.04M | 18.70%597.23M | 109.44%137.55M | 21.94%222.91M | 11.75%154.85M | -28.65%82.83M | -35.93%503.14M | -50.79%65.67M |
Net non-operating interest income expense | -5.07%12.18M | 23.46%14.64M | 60.70%15.79M | 176.23%50.64M | 84.15%16.13M | 174.94%12.83M | 242.76%11.86M | 578.12%9.83M | 1,371.19%18.33M | 1,841.91%8.76M |
Non-operating interest income | -5.07%12.18M | 23.46%14.64M | 60.70%15.79M | 176.23%50.64M | 84.15%16.13M | 174.94%12.83M | 242.76%11.86M | 578.12%9.83M | 1,371.19%18.33M | 1,841.91%8.76M |
Other net income (expense) | -151.38%-1.63M | -59.14%304K | 80.21%-3.44M | 54.67%-26.27M | 54.57%-9.88M | 86.02%-650K | 102.03%744K | -447.16%-17.4M | -440.93%-57.94M | -892.24%-21.74M |
Gain on sale of security | -620.10%-2.83M | 85.02%-273K | 77.98%-3.06M | 18.17%-19.12M | 16.88%-3.02M | -139.14%-393K | 92.92%-1.82M | -377.09%-13.89M | -362.24%-23.37M | -102.56%-3.64M |
Special income (charges) | 86.89%-110K | -112.81%-229K | 89.01%-386K | 79.34%-7.14M | 74.70%-4.58M | 85.16%-839K | 116.53%1.79M | ---3.51M | -511.26%-34.57M | -4,482.78%-18.1M |
-Less:Restructuring and merger&acquisition | -86.89%110K | 112.81%229K | -89.01%386K | -89.54%3.62M | -94.18%1.05M | -85.16%839K | -116.53%-1.79M | --3.51M | 2,672.40%34.57M | 4,482.78%18.1M |
-Less:Impairment of capital assets | ---- | ---- | ---- | --3.53M | ---- | ---- | ---- | ---- | --0 | ---- |
Other non- operating income (expenses) | 124.40%1.31M | 3.60%806K | ---- | ---- | ---- | --582K | --778K | ---- | ---- | ---- |
Income before tax | 4.30%245.21M | 5.14%176.07M | 122.42%167.39M | 34.10%621.6M | 172.90%143.8M | 28.59%235.09M | 58.78%167.45M | -38.59%75.26M | -40.25%463.52M | -60.00%52.69M |
Income tax | 569.68%45.06M | 0.82%30.58M | 103.94%25.56M | -90.45%9.45M | -312.75%-23.82M | -122.49%-9.59M | 29.79%30.33M | -42.29%12.53M | -24.64%98.95M | -52.39%11.2M |
Net income | -18.20%200.15M | 6.10%145.48M | 126.11%141.83M | 67.91%612.14M | 303.94%167.62M | 74.58%244.68M | 67.03%137.12M | -37.79%62.73M | -43.43%364.58M | -61.65%41.5M |
Net income continuous Operations | -18.20%200.15M | 6.10%145.48M | 126.11%141.83M | 67.91%612.14M | 303.94%167.62M | 74.58%244.68M | 67.03%137.12M | -37.79%62.73M | -43.43%364.58M | -61.65%41.5M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -18.20%200.15M | 6.10%145.48M | 126.11%141.83M | 67.91%612.14M | 303.94%167.62M | 74.58%244.68M | 67.03%137.12M | -37.79%62.73M | -43.43%364.58M | -61.65%41.5M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -18.20%200.15M | 6.10%145.48M | 126.11%141.83M | 67.91%612.14M | 303.94%167.62M | 74.58%244.68M | 67.03%137.12M | -37.79%62.73M | -43.43%364.58M | -61.65%41.5M |
Basic earnings per share | -15.29%1.33 | 9.20%0.95 | 138.46%0.93 | 73.33%3.9 | 319.23%1.09 | 80.46%1.57 | 74.00%0.87 | -36.07%0.39 | -41.56%2.25 | -60.00%0.26 |
Diluted earnings per share | -14.84%1.32 | 10.47%0.95 | 135.90%0.92 | 73.54%3.87 | 311.54%1.07 | 80.23%1.55 | 72.00%0.86 | -36.07%0.39 | -41.01%2.23 | -59.38%0.26 |
Dividend per share | 0 | 19.02%1.3789 | 0 | 17.43%1.1585 | 0 | 0 | 17.43%1.1585 | 0 | 5.42%0.9866 | 0 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |